미국 - 영어 - NLM (National Library of Medicine)

bryant ranch prepack - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations(8.7)  and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of alfuzo

미국 - 영어 - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations(8.7)  and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1)and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of al

이스라엘 - 영어 - Ministry of Health

teva israel ltd - alfuzosin hydrochloride - tablets extended release - alfuzosin hydrochloride 10 mg - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy particularly if surgery has to be delayed for some reason. adjuvant treatment to a catheter in acute urinary retention related to benign prostatic hypertrophy.

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

milpharm limited - alfuzosin hydrochloride - tablet prolonged release - 10 milligram - alpha-adrenoreceptor antagonists

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

rowex ltd - alfuzosin hydrochloride - prolonged-release tablet - 10 milligram(s) - alpha-adrenoreceptor antagonists; alfuzosin

캐나다 - 영어 - Health Canada

pro doc limitee - alfuzosin hydrochloride - tablet (extended-release) - 10mg - alfuzosin hydrochloride 10mg - selective alfa-1-adrenergic blocking agents

캐나다 - 영어 - Health Canada

sivem pharmaceuticals ulc - alfuzosin hydrochloride - tablet (extended-release) - 10mg - alfuzosin hydrochloride 10mg - selective alfa-1-adrenergic blocking agents

캐나다 - 영어 - Health Canada

sanis health inc - alfuzosin hydrochloride - tablet (extended-release) - 10mg - alfuzosin hydrochloride 10mg - selective alfa-1-adrenergic blocking agents

미국 - 영어 - NLM (National Library of Medicine)

golden state medical supply, inc. - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in the pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [ see use in specific populations ( 8.7) and clinical pharmacology ( 12.3) ].  in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [ see use in specific populations ( 8.7) and clinical pharmacology ( 12.3) ].  - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, a

이스라엘 - 영어 - Ministry of Health

sanofi israel ltd - alfuzosin hydrochloride - tablets sustained release - alfuzosin hydrochloride 5 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason